Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04809012
Other study ID # PDL1-RRST-201
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date June 2021
Est. completion date June 2024

Study information

Verified date March 2022
Source Sorrento Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the efficacy of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected solid tumors.


Description:

This is an open-label, multicenter, Phase 2 basket study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of STI-3031, an anti-PD-L1 antibody, in patients with selected RRSTs. All participants will receive STI-3031 20 mg/kg every 2 weeks (Q2W) via IV infusion over approximately 60 minutes.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score = 2 - Has histologically- or cytologically-confirmed relapsing or refractory solid tumor and subject has exhausted all approved options that may, in the investigator's opinion, produce clinical benefit. - Has at least one measurable disease per RECIST 1.1 - May have been treated with radiation therapy (RT) provided there is measurable disease outside the field of RT. Prior systemic RT must be completed at least 4 weeks before the first dose of study intervention. Prior focal radiotherapy must be completed at least 2 weeks before the first dose of study intervention. No radiopharmaceuticals are permitted within 8 weeks before the first dose of study intervention. - Life expectancy of at least 16 weeks per investigator assessment - Must have adequate hematologic, hepatic and renal function as assessed by specific laboratory criteria - Willing to sign the informed consent form and comply with the study schedule and all other protocol requirements - Females of childbearing potential (FCBP) must have a negative pregnancy test during the Screening Period prior to treatment. All heterosexually active FCBP and all heterosexually active male patients must agree to use effective double barrier methods of birth control throughout the study. - At time of the first dose of study intervention, at least 14 days or 5 half-lives, whichever is shorter, since the last chemotherapy, immunotherapy, biological or investigational therapy, and have recovered from toxicities associated with such treatment to < Grade 2. Exclusion Criteria: - Previously treated with an anti-PD-L1 or anti-PD-1 antibody - Known presence of symptomatic central nervous system (CNS) metastases unless considered adequately treated and off corticosteroids and/or anticonvulsant therapy for at least 2 weeks prior to first dose of study intervention. - Prior allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. Prior autologous HSCT is allowed. - Any other malignancy, excluding basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or localized prostate cancer, from which the participant has not been disease-free for at least 2 years. - Any active autoimmune disease requiring treatment within the past 3 months or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo, hormone replacement therapy for stable thyroid diseases and Type 1 diabetes mellitus. - Evidence of active or latent tuberculosis (TB) infection - Known viral infection with COVID-19, hepatitis B virus (HBV) hepatitis C virus (HCV), unless participant, as applicable, is negative on RT-PCR or rapid antigen tests, has been vaccinated, and has completed curative antiviral treatment and viral load is below the limit of quantification. - Known active viral infection with human immunodeficiency virus (HIV) - Active infection (viral, bacterial, or fungal) requiring intravenous (IV) systemic therapy within 14 days prior to the first dose of study intervention. - Evidence of bleeding diathesis or coagulopathy. - Conditions requiring chronic steroid use (> 10 mg/day of prednisone or equivalent). - Recent history of attenuated viral vaccination within 30 days prior to the first dose of study intervention. - Herbal preparations/medications are not allowed throughout the treatment period unless first discussed with and approved by the Medical Monitor. - History of severe hypersensitivity reactions to other monoclonal antibodies or known hypersensitivity to the study intervention or its excipients. - Known current drug or alcohol abuse - Major surgical procedures = 28 days prior to the first dose of study intervention, or minor surgical procedures = 7 days prior to the first dose of study intervention. No waiting is required following port-a-catch placement or similar venous access device. - Pregnant or lactating or intending on either during the study - Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure NYHA III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 3 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia). - Underlying medical conditions that, in the Investigator's opinion, will make the administration of study intervention hazardous or obscure the interpretation of toxicity determination or AEs, including psychiatric illness or social situation that would preclude study compliance.

Study Design


Intervention

Biological:
STI-3031
STI-3031 is an anti-PD-L1 antibody

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sorrento Therapeutics, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate Objective response rate (ORR) as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria Baseline through study completion at up to approximately 3 years
Secondary Safety as assessed by incidence and severity of adverse events Incidence of treatment-emergent adverse events and their relationships to STI-3031 Baseline through study completion at up to approximately 3 years
Secondary Duration of Response Duration of response (DOR) as assessed using RECIST 1.1 Baseline through study completion at up to approximately 3 years
Secondary Complete response rate and duration Complete response (CR) rate and duration of CR as assessed using RECIST 1.1 Baseline through study completion at up to approximately 3 years
Secondary Progression-Free Survival Progression-free survival (PFS) and 12-month PFS as assessed using RECIST 1.1 Baseline through study completion at up to approximately 3 years
Secondary Event-free survival Event-free survival (EFS) as assessed using RECIST 1.1 Baseline through study completion at up to approximately 3 years
Secondary Overall survival Overall survival (OS) as assessed using RECIST 1.1 Baseline through study completion at up to approximately 3 years
Secondary Time to next treatment Time to next treatment (TTNT) Baseline through study completion at up to approximately 3 years
Secondary Incidence of anti-drug antibody Incidence of anti-drug antibody (ADA) and correlation with exposure and activity as measured using serum titers of anti-STI-3031 antibodies Baseline through study completion at up to approximately 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2